Enliven Therapeutics News

A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40

Moomoo NewsNov 15 08:00 ET · Ratings

Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

BenzingaNov 15 07:19 ET

Enliven Therapeutics Reports Q3 Results and Clinical Progress

TipRanksNov 14 23:34 ET

Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32

ReutersNov 14 09:40 ET

Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating

TipRanksNov 13 18:35 ET

Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026

ReutersNov 13 16:33 ET

Enliven Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 16:20 ET · Announcements

Enliven Therapeutics | 8-K: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

SECNov 13 16:16 ET

Express News | Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate

BenzingaNov 13 16:15 ET

Express News | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

ReutersNov 13 16:05 ET

Express News | Enliven Therapeutics Q3 Income From Operations USD -27.068 Million

ReutersNov 13 16:05 ET

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BenzingaOct 31 11:37 ET

Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading

Dow JonesOct 31 07:22 ET · Ratings

JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36

Moomoo NewsOct 30 16:31 ET · Ratings

H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37

Moomoo NewsOct 1 09:31 ET · Ratings

Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate

TipRanksOct 1 08:35 ET · Ratings

TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating

Moomoo NewsSep 30 07:33 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)

TipRanksSep 30 01:50 ET · Ratings

LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsSep 29 09:31 ET · Ratings

Enliven Therapeutics Announces Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia; Reported Cumulative MMR Rate Of 44% (8/18) By 24 Weeks, With Stable Or Deepening Responses Between Weeks 12 And 24, Which Continues To...

BenzingaSep 28 09:42 ET